CAD and hepatocellular carcinoma: It has been established that CAD is the rate‐limiting enzyme that catalyzes aspartate participating in de novo pyrimidine synthesis,[46, 47] which has been linked to enhanced tumor stemness properties.[48] The increase in intracellular aspartate levels, which, under the catalysis of CAD, facilitating de novo pyrimidine synthesis, thus enhancing the stemness properties in HCC.